Praxis Precision Medicines, Inc. PRAX Ulixacaltamide — Program-specific expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses?
- Praxis Precision Medicines, Inc. (PRAX) reported ulixacaltamide — program-specific expenses of $19.1M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses changed year-over-year?
- Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses decreased by 18.8% year-over-year, from $23.51M to $19.1M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses has grown at a 80.2% compound annual growth rate (CAGR), from $19.46M to $63.21M.
- What does ulixacaltamide — program-specific expenses mean?
- The total direct costs incurred to develop and support the Ulixacaltamide drug program.
- How do you interpret ulixacaltamide — program-specific expenses?
- An increase typically reflects accelerated clinical trial activity or commercial preparation, while a decrease may indicate program completion, budget optimization, or strategic reprioritization.
- How does ulixacaltamide — program-specific expenses compare across companies?
- Comparable to R&D program-specific spend or direct product development costs reported by other clinical-stage biopharmaceutical companies.